Coronary heart disease
Conditions
Interventions
Intensive early lipid-lowering:Including cholesterol absorption inhibitors, statins, PCSK9 inhibitors, or lipid-lowering drugs such as inclisiran, a small interfering RNA.
Sustained intensive lipid-lowering (control group):Including cholesterol absorption inhibitors, statins, PCSK9 inhibitors, or lipid-lowering drugs such as inclisiran, a small interfering RNA.
Sponsors
The Seventh Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Originally diagnosed CHD patients with aged between 18-70 years old;
Exclusion criteria
Exclusion criteria: 1. Aged under 18 years or over 75 years; 2.Old myocardial infarction; 3.History of previous coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI); 4.History of ischemic or hemorrhagic stroke with residual neurological dysfunction; 5.Symptomatic peripheral vascular disease; 6.More than two severe cardiovascular events occurring consecutively within 2 years; 7.Complicated with middle-advanced stage tumor; 8.Life expectancy = 3 times the upper limit of normal) or renal insufficiency (serum creatinine (Cr) > 1.5 times the upper limit of normal); 10.Known allergy or intolerance to cholesterol absorption inhibitors, statins, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc); 11.Baseline New York Heart Association (NYHA) functional class >= III-IV; 12.Pregnancy, lactation period, or ongoing participation in another clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Atherosclerotic lesion progression;Major adverse cardiovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug safety; | — |
Countries
China
Contacts
Public ContactJianlei Zheng
The Seventh Affiliated Hospital Sun Yat-sen University
Outcome results
None listed